Ferric Carboxymaltose
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Ferric Carboxymaltose: From Intravenous Iron Replacement to Bronchitis
One-Sentence Summary
Ferric carboxymaltose is an intravenous iron replacement product (US brand: Injectafer), used to correct iron deficiency and iron-deficiency anemia. The TxGNN model predicts it may be effective for bronchitis, but 0 clinical trials and 0 publications currently support this direction. The prediction rests on the model score alone, so the evidence is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the supplied data (established use: intravenous iron replacement for iron deficiency) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.00% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 records (all under the same NDA, NDA203565) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ferric carboxymaltose is an intravenous iron replacement product. Its established role is correcting iron deficiency and iron-deficiency anemia, and the supplied data does not include its label indication text. No mechanistic link to bronchitis is supported by the supplied data.
Any link is speculative. Iron deficiency may affect immune function and susceptibility to respiratory infection, which could loosely connect iron repletion to respiratory illness. On the other hand, iron availability may promote microbial growth and oxidative stress. A benefit in bronchitis therefore cannot be assumed and could be adverse.
The high TxGNN score (0.99, rank 21,403) is a knowledge-graph prediction only. No clinical, preclinical, or literature evidence was provided to support or refute it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA203565 | Injectafer (American Regent, Inc.) | Injection, solution | Not provided in the supplied data |
The supplied data lists three identical records under this NDA. They are shown once here.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score (L5), with no trials or publications. No mechanism links intravenous iron to bronchitis, and iron could plausibly worsen infection-related conditions.
To proceed, the following is needed:
- The FDA package insert (warnings, contraindications, approved indications), which is a blocking gap for safety screening
- Mechanism of action data (for example, from DrugBank) to allow mechanistic-link analysis
- A targeted literature and trial search on iron status, iron supplementation, and bronchitis or respiratory infection outcomes
- Preclinical or observational evidence that iron repletion is not harmful in respiratory infection
- A route and formulation assessment, since only an intravenous injection is marketed and no route compatibility has been established for bronchitis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.